Summit Therapeutics Inc. — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Akeso's HARMONi-2 trial (n=398, China-based) showed ivonescimab monotherapy achieved median OS of 30.8 months vs. 22.6 months for pembrolizumab (HR 0.73, p=0.009)—a 27% death-risk reduction. In the PD-L1 high subgroup (n=168), HR was 0.58. Summit is advancing the global Phase III HARMONi-7 study (target 780 patients, ongoing enrollment) and a BLA for combination therapy (HARMONi) with FDA PDUFA date November 14, 2026.
Why this rating
Positive pivotal OS data strengthens ivonescimab's regulatory/commercial case; material for $2.5B company. BLA pending, multi-indication pipeline active. Not business-transforming yet (approval uncertain, China-only data), but clinically significant milestone.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $18.17 ▲ 0.33% | at our read · unknown $18.11 | +10 min · unknown $18.52 ▲ 2.26% | +30 min · unknown $18.41 ▲ 1.68% | +1 hr · unknown $18.26 ▲ 0.83% | +4 hrs pending |
The stock had already moved -0.33% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.